LIGAND PHARMACEUTICALS INC
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Ligand Pharmaceuticals is a biopharmaceutical company that licenses its drug technologies and royalty-bearing assets to other pharmaceutical companies, earning revenue from royalties, milestone payments, and licensing fees rather than selling its own marketed drugs directly. Its portfolio includes technologies such as Captisol, a formulation platform used to improve drug solubility and stability, alongside stakes in partnered programs across various therapeutic areas.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Reardon AndrewCLO & Secretary | Sell | $162K | 522at $309.91 | Nov 2, 2026 |
| Reardon AndrewCLO & Secretary | Sell | $25K | 80at $314.58 | Nov 2, 2026 |
| Aryeh JasonDirector | Sell | $90K | 282at $319.99 | Nov 4, 2026 |
| Reardon AndrewCLO & Secretary | Sell | $140K | 440at $318.73 | Nov 2, 2026 |
| Reardon AndrewCLO & Secretary | Sell | $126K | 403at $313.75 | Nov 2, 2026 |
| Reardon AndrewCLO & Secretary | Sell | $198K | 634at $312.85 | Nov 2, 2026 |
| Reardon AndrewCLO & Secretary | Sell | $102K | 320at $319.97 | Nov 2, 2026 |
| Reardon AndrewCLO & Secretary | Sell | $39K | 120at $323.14 | Nov 2, 2026 |
| Reardon AndrewCLO & Secretary | Sell | $64K | 200at $321.44 | Nov 2, 2026 |
| Reardon AndrewCLO & Secretary | Sell | $89K | 280at $317.91 | Nov 2, 2026 |
| Reardon AndrewCLO & Secretary | Sell | $152K | 490at $310.61 | Nov 2, 2026 |
| Reardon AndrewCLO & Secretary | Sell | $218K | 708at $308.43 | Nov 2, 2026 |
| Reardon AndrewCLO & Secretary | Sell | $87K | 283at $307.39 | Nov 2, 2026 |
| Reardon AndrewCLO & Secretary | Sell | $162K | 520at $311.72 | Nov 2, 2026 |
| Aryeh JasonDirector | Sell | $224K | 700at $320.43 | Nov 2, 2026 |
| Aryeh JasonDirector | Sell | $387K | 1,209at $320.42 | Oct 30, 2026 |
| Aryeh JasonDirector | Sell | $17K | 52at $320.24 | Oct 30, 2026 |
| Aryeh JasonDirector | Sell | $16K | 50at $320.49 | Oct 30, 2026 |
| Aryeh JasonDirector | Sell | $16K | 50at $317.74 | Oct 30, 2026 |
| Aryeh JasonDirector | Sell | $16K | 50at $318.23 | Oct 30, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable LGND activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.